动物造模,高尿酸血症动物模型 z-bio 2022-01-07 759

　　Objective: To explore a reliable method to establish a rat model of uric acid excretion hyperuricemia, and to lay a foundation for studying the etiology of uric acid excretion hyperuricemia and optimizing the treatment plan.

　　"Method: Potassium oxalate (300 mg/kg), pyrazinamide (300 mg/kg), ethambutol (250 mg/kg) were used to collaborate to establish a model. The administration was continued for 1, 3, and 5 weeks to detect the levels of uric acid in the blood, urine and feces of the rats, and to detect and observe the liver and kidney functions at the same time. Histopathological section.

　　"Results: During the continuous administration, the blood uric acid of rats with the combination of potassium oxazine and ethambutol first increased and then decreased, and the blood uric acid of the combination of potassium oxazosin and pyrazinamide increased. And the uric acid in the urine is elevated. steadily. Neither method will cause significant damage to the liver and kidneys.

　　Conclusion: The combination of potassium oxalate and pyrazinamide can effectively establish a rat model of excretory phosphate dysregulation hyperuricemia. The model is stable. The cause is uric acid excretion hyperuricemia, which is more consistent with the clinical course.